抗人胰腺癌单克隆抗体介导LAK细胞体外体内抗胰腺癌作用的研究

THE ANTI-PANCREATIC CANCER EFFICACY OF LAK CELLS MEDIATED BY YPC3 MONOCLONALANTIBODY IN VITRO AND IN VIVO

体外４小时５１Ｃｒ释放试验表明，抗人胰腺癌单克隆抗体（ＹＰＣ３ＭｃＡｂ）能增强ＬＡＫ细胞对Ｃａｐａｎ－２人胰腺癌细胞的杀伤作用，这种ＬＡＫ细胞的抗体依赖性细胞介导的细胞毒作用（ＡＤＣＣ），随ＹＰＣ３ＭｃＡｂ的浓度增加而加强，５０μｇ／ｍｌ的ＹＰＣ３ＭｃＡｂ增加ＬＡＫ细胞的杀伤率约６０％。而对照抗体无此作用。裸鼠体内实验表明，ＹＰＣ３ＭｃＡｂ和ＬＡＫ细胞同时使用，能完全阻止Ｃａｐａｎ－２细胞的生长，优于ＬＡＫ细胞、脾细胞和ＹＰＣ３ＭｃＡｂ的分别作用。结果提示，ＹＰＣ３ＭｃＡｂ和ＬＡＫ细胞的联合应用，对胰腺癌治疗有一定价值。

Abstract The purpose of this study was to investigate a new form of specific targeting immunotherapyfor human pancreatic carcinoma. In 4hr 51Cr release assays, the cytolysis of Capan-2 humanpancreatic carcinoma cells by LAK cells was enhanced with pancreatic cancer-specific monoclonalantibody (YPC3 McAb).This antibody-dependent cellular cytotoxicity (ADCC)of the LAK cellswas more evident while increasing the concentration of YPC3 McAb. The cytotoxic effects of theLAK cells on target cells increased about 60% when 50μg/ml of YPC3 McAb was used. Nocytotoxic effect of the LAK cells was found in the presence of irrelevant monoclonal antibody.Experimentally, the growth rate of Capan-2 human pancreatic carcinoma cell line nude micewas 25%,100%,and 100% after the injection of LAK cells, splenocytes and YPC3 McAb,respectively. However, simulataneous injection of YPC3 McAb and LAK completely inhibited the growth of the cell. line these results suggest that LAK cells in combination with YPC3 McAb mightbe useful for the treatment of human pancreatic carinoma.